Rapid Micro Biosystems

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company. It provides mission critical automation solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus in 2006 and is headquartered in Lowell, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rapid Micro Biosystems surpasses Q1 revenue targets, eyes global expansion

Rapid Micro Biosystems delivered a strong Q1 performance, exceeding revenue guidance and setting new records in consumable sales.
The company's focus on product innovation and customer-centric solutions positions it well for sustained growth and market expansion.
While challenges in revenue targets and margin improvements exist, strategic planning and operational enhancements offer opportunities for future success.

Rapid Micro Biosystems reports strong Q2 growth and cost-saving initiatives

Rapid Micro Biosystems showcased robust revenue growth and margin improvement in Q2 2024, driven by successful customer engagement and product placements.
While challenges like net losses persist, the company's proactive cost management and revenue outlook reaffirmation signal a commitment to financial health.
Opportunities lie in achieving positive cash flow by 2027, sustained revenue growth, and operational efficiency enhancements for long-term success.

Rapid Micro Biosystems achieves record revenue and focuses on growth

Rapid Micro Biosystems reported strong Q3 performance with record revenue and improved gross margins.
The company's commercial strategy and product launches are driving customer engagement and sales growth.
While challenges like achieving positive cash flow exist, opportunities for revenue growth through new modalities are promising.
Strategic planning and operational efficiency will be key in navigating market dynamics and sustaining growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rapid Micro Biosystems, Inc. is a life sciences technology company. It provides automated solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus on December 29, 2006 and is headquartered in Lexington, MA.

Reports third quarter 2022 commercial revenue of $4.7 million

Rapid Micro Biosystems Reports Third Quarter 2022 Financial Results

LOWELL, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its newest product, RMBNucleus™ Mold Alarm, which is designed to rapidly detect environmental molds in the pharmaceutical manufacturing process. RMBNucleus™ Mold Alarm is expected to be available on the Growth Direct® System before the end of 2022.

Rapid Micro Biosystems Announces RMBNucleus™ Mold Alarm for the Growth Direct® System

LOWELL, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its participation as a sponsor and exhibitor at the 2022 Parenteral Drug Association (“PDA”) Pharmaceutical Microbiology Conference on October 10-12, in Washington, D.C.

Rapid Micro Biosystems to Exhibit at the 2022 PDA Pharmaceutical Microbiology Conference

LOWELL, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Chief Executive Officer, Robert Spignesi, will speak at the 2022 PDA/FDA Joint Regulatory Conference on Wednesday, September 14th.

Rapid Micro Biosystems CEO Rob Spignesi to Speak at the 2022 PDA/FDA Joint Regulatory Conference

Hill International

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Hill International, Rapid Micro Biosystems See Activist Investor Action

Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Mike Beaulieu - CFA Vice President, Investor Relations & Corporate Communications Rob Spignesi - Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dan Arias - Stifel Stephanie Yan - Cowen Rachel Cascio - JPMorgan Operator Ladies and gentlemen, thank you for standing by and welcome to the Rapid Micro Biosystems Second Quarter 2022 Earnings Conference Call. I would now like to turn the call over to Mike Beaulieu, Investor Relations.

Rapid Micro Biosystems, Inc. (RPID) CEO Rob Spignesi on Q2 2022 Results - Earnings Call Transcript

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.43% and 24.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Lags Revenue Estimates

Rejects Unsolicited, Non-Binding Proposal from Kennedy Lewis Investment Management

Rapid Micro Biosystems Announces Review of Strategic Alternatives to Maximize Shareholder Value

Reports second quarter 2022 commercial revenue of $3.9 million

Rapid Micro Biosystems Provides Business Update and Reports Second Quarter 2022 Financial Results

LOWELL, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2022 financial results on Friday, August 12, prior to the market open.

Rapid Micro Biosystems to Announce Second Quarter 2022 Financial Results on August 12, 2022

Shareholders Do Not Need to Take Action at This Time Shareholders Do Not Need to Take Action at This Time

Rapid Micro Biosystems Confirms Receipt of Unsolicited, Non-Binding Proposal from Kennedy Lewis Investment Management

NEW YORK , June 30, 2022 /PRNewswire/ -- Kennedy Lewis Investment Management LLC today sent the following letter to the Board of Directors of Rapid Micro Biosystems, Inc. (NASDAQ: RPID): To the Board of Directors: Kennedy Lewis Investment Management LLC (" Kennedy Lewis ") is interested in discussing a potential acquisition of Rapid Micro Biosystems, Inc. (" RPID "). Kennedy Lewis is an opportunistic credit manager founded in 2017 with approximately $10 billion under management across private funds and CLOs.

Kennedy Lewis Investment Management LLC Announces Offer to Acquire Rapid Micro Biosystems

Rapid Micro Biosystems Inc. (NASDAQ:RPID ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Michael Beaulieu - CFA Vice President, Investor Relations and Corporate Communications Robert Spignesi - President and Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Noah Burhance - JPMorgan Operator Good day, and thank you for standing by. Welcome to the Rapid Micro Biosystems First Quarter 2022 Earnings Conference Call.

Rapid Micro Biosystems Inc. (RPID) CEO Robert Spignesi on Q1 2022 Results - Earnings Call Transcript

Reports first quarter 2022 commercial revenue of $4.2 million

Rapid Micro Biosystems Reports First Quarter 2022 Financial Results

LOWELL, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2022 financial results on Tuesday, May 10, 2022, prior to the market open.

Rapid Micro Biosystems to Announce First Quarter 2022 Financial Results on May 10, 2022

The mean of analysts' price targets for Rapid Micro Biosystems, Inc. (RPID) points to a 309.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Rapid Micro Biosystems, Inc. (RPID) Could Surge 310%: Read This Before Placing a Bet

The consensus price target hints at a 214.9% upside potential for Rapid Micro Biosystems, Inc. (RPID). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Rapid Micro Biosystems, Inc. (RPID) Have the Potential to Rally 215% as Wall Street Analysts Expect?

Rapid Micro Biosystems Inc. (RPID) CEO Rob Spignesi on Q4 2021 Results - Earnings Call Transcript

Reports fourth quarter 2021 total revenue of $5.2 million and commercial revenue of $4.9 million

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2021 Financial Results and Reaffirms Full Year 2022 Guidance

LOWELL, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will participate in the Cowen 42nd Annual Health Care Conference.

Rapid Micro Biosystems to Participate at the Cowen 42nd Annual Health Care Conference

LOWELL, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro” or the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2021 financial results on Friday, March 4, 2022, prior to the market open.

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2021 Financial Results on March 4, 2022

New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Rapid Micro Biosystems, Inc. ("Rapid Micro" or the "Company") (NASDAQ: RPID). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Rapid Micro and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid Micro Biosystems, Inc. - RPID

LOWELL, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the appointment of Michael Beaulieu as Vice President, Investor Relations and Corporate Communications.

Rapid Micro Biosystems Appoints Michael Beaulieu as Vice President, Investor Relations and Corporate Communications

Full year 2021 commercial revenue expected to be between $21.3 million and $21.7 million

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue and Provides 2022 Revenue Outlook

LOWELL, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Inese Lowenstein to its Board of Directors.

News for Rapid Micro Biosystems Stock (RPID)